EUVIMEDEUVIMED entdecken
Crossref

Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens

Mengyuan Yin, Zhongmin Liu, Yang Zhou, Wei Li, Jing Yan, Desheng Cao, Lichen Yin

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.07.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Mengyuan Yin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory of Carbon-Based Functional Materials & Devices, Collaborative Innovati…. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Cancer Vaccines, Nanoparticles, Tumor Microenvironment. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer vaccines based on single-source (exogenous or endogenous) tumor-associated antigens (TAAs) are often challenged by the insufficient T cell response and the immunosuppressive tumor microenvironment (TME). Herein, a dual TAAs-boosted nanovaccine based on cancer cell (4T1) membrane-cloaked, CO-immobilized Prussian blue nanoparticles (4T1-PB-CO NPs) is developed and coupled with anti-interleukin (IL)-10 therapy to maximize the efficacy of antitumor immunotherapy. 4T1 cell membrane not only endows NPs with tumor targeting ability, but also serves as exogenous TAAs to trigger CD4+ T cell response and M1-phenotype polarization of tumor-associated macrophages. Under near-infrared light irradiation, 4T1-PB-CO NPs release CO to induce immunogenic cell death (ICD) of tumor cells, thus generating endogenous TAAs to activate CD8+ T cell response. Meanwhile, ICD triggers release of damage-associated molecular patterns, which can promote DC maturation to amplify the antitumor T cell response. When combined with anti-IL-10 that reverses the immunosuppressive TME, 4T1-PB-CO NPs efficiently suppress the primary tumors and produce an abscopal effect to inhibit distant tumors in a breast tumor-bearing mouse model. Such a two-pronged cancer vaccine represents a promising paradigm for robust antitumor immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmCancer VaccinesNanoparticlesTumor MicroenvironmentMice, Inbred BALB CAnimalsFemaleCell Line, TumorFerrocyanidesInterleukin-10MiceImmunotherapyCD8-Positive T-LymphocytesNanovaccines

Stichwörter der Autor:innen

Cancer immunotherapyCarbon monoxideImmunogenic cell deathMacrophage polarizationTumor cell membrane-cloaked nanoparticles

Substanzen

Antigens, NeoplasmCancer Vaccinesferric ferrocyanideFerrocyanidesInterleukin-10Nanovaccines

Autor:innen und Institutionen

  • Institute of Functional Nano & Soft Materials (FUNSOM), Jiangsu Key Laboratory of Carbon-Based Functional Materials & Devices, Collaborative Innovation Center of Suzhou Nano Science & Technology, Soochow University, Suz…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yin, M., Liu, Z., Zhou, Y., Li, W., Yan, J., Cao, D., & Yin, L. (2024). Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.07.024

Vancouver

Yin M, Liu Z, Zhou Y, Li W, Yan J, Cao D, et al. Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.07.024

BibTeX
@article{Yin2024,
  author = {Yin, Mengyuan and Liu, Zhongmin and Zhou, Yang and Li, Wei and Yan, Jing and Cao, Desheng and Yin, Lichen},
  title = {Two-pronged anti-cancer nanovaccines enpowered by exogenous/endogenous tumor-associated antigens},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.07.024}
}
Kostenlos starten →